4.6 Article

The Effects of a Blood-Brain Barrier Penetrating Erythropoietin in a Mouse Model of Tauopathy

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Geriatrics & Gerontology

Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy

Henika Patel et al.

Summary: Pathological aggregation of tau and neuroinflammatory changes are crucial in the clinical course of Alzheimer's disease and related tauopathies. The PS19 mouse model study suggests that different pathological tau species may be associated with different functional deficits, and neuroinflammation may contribute to functional deficits independently of tau pathology.

NEUROBIOLOGY OF AGING (2022)

Article Medicine, Research & Experimental

Medha Plus-A novel polyherbal formulation ameliorates cognitive behaviors and disease pathology in models of Alzheimer?s disease

Ramesh Kumar Paidi et al.

Summary: Alzheimer's disease is a complex neurodegenerative disorder with no complete cure. The development of multi-component drugs that target multiple molecular targets is crucial for improving cognitive deficits and pathological manifestations associated with Alzheimer's disease.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Article Pharmacology & Pharmacy

Efficacy and Safety of a Brain-Penetrant Biologic TNF-α Inhibitor in Aged APP/PS1 Mice

Weijun Ou et al.

Summary: TNF-alpha inhibitors play a crucial role in the pathology of Alzheimer's disease, and delivering them to the brain can enhance their therapeutic effects. In this study, the fusion of TNF-alpha receptor with a transferrin receptor antibody showed better therapeutic outcomes in aged APP/PS1 mice compared to other TNF-alpha inhibitors, without causing any hematological or iron-related dysregulation.

PHARMACEUTICS (2022)

Article Clinical Neurology

2022 Alzheimer's disease facts and figures

Joseph Gaugler et al.

Summary: This article discusses the impact of Alzheimer's disease on public health, including its incidence, prevalence, mortality and morbidity rates, healthcare costs and caregivers' burden. It also addresses the perspectives of consumers and primary care physicians on mild cognitive impairment (MCI) and the need for improved awareness, diagnosis, and treatment. The article emphasizes the increasing number of individuals living with Alzheimer's and the challenges faced by caregivers and healthcare providers, particularly during the COVID-19 pandemic.

ALZHEIMERS & DEMENTIA (2022)

Article Biotechnology & Applied Microbiology

A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II

Torayuki Okuyama et al.

Summary: The study demonstrated that pabinafusp alfa is a potentially effective treatment for both the central and peripheral symptoms of MPS-II patients, with the ability to cross the blood-brain barrier to reach the central nervous system. In the 52-week clinical trial, the drug showed relatively good efficacy and safety profiles.

MOLECULAR THERAPY (2021)

Article Clinical Neurology

Erythropoietin-derived peptide treatment reduced neurological deficit and neuropathological changes in a mouse model of tauopathy

Yun-Beom Choi et al.

Summary: Treatment of PS19 mice with JM4 before disease onset reduced neurological deficits, prolonged lifespan, and rescued memory impairment. The beneficial effects were accompanied by reductions in neuronal loss, phosphorylated tau aggregation, and microglial activation in the PS19 mouse brain, suggesting JM4 as a potential novel therapeutic agent for tauopathies including AD and related dementias.

ALZHEIMERS RESEARCH & THERAPY (2021)

Article Immunology

Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy

Weijun Ou et al.

Summary: The study demonstrated that both BBB-penetrating and non-BBB-penetrating biologic TNF inhibitors showed therapeutic effects in the PS19 mouse model of tauopathy, significantly improving neuronal health and phosphorylated tau levels.

JOURNAL OF NEUROINFLAMMATION (2021)

Article Biochemistry & Molecular Biology

Behavioural Functions and Cerebral Blood Flow in a P301S Tauopathy Mouse Model: A Time-Course Study

Faraz Ahmad et al.

Summary: PS19 mice with MAPT P301S mutation exhibit hyperactivity, reduced anxiety levels, spatial working memory deficits, reduced resting neocortical CBF, and increased phosphorylated tau with age. This study provides evidence for the utility of the PS19 mouse model in studying neurodegenerative events associated with tauopathy and tau dysfunction.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Genetics & Heredity

Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II

Ryuji Yamamoto et al.

Summary: Pabinafusp alfa is a fusion protein developed to target central nervous system-related symptoms in patients with MPS II. Nonclinical safety assessment showed that it did not exhibit effector functions or significant toxicological changes in animal studies, indicating minimal impact on the iron transport system. These findings suggest that pabinafusp alfa is expected to be safe for long-term use in individuals with MPS II.

MOLECULAR GENETICS AND METABOLISM REPORTS (2021)

Article Biochemistry & Molecular Biology

Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype

Huifangjie Li et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Article Pharmacology & Pharmacy

Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice

Demi M. Castellanos et al.

PHARMACEUTICS (2020)

Review Neurosciences

Intersection of pathological tau and microglia at the synapse

Thomas Vogels et al.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)

Review Neurosciences

The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease

Jiahong Sun et al.

NEUROMOLECULAR MEDICINE (2019)

Article Clinical Neurology

Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice

Jiahong Sun et al.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2019)

Review Neurosciences

The Role of Microglia in the Spread of Tau: Relevance for Tauopathies

Juan R. Perea et al.

FRONTIERS IN CELLULAR NEUROSCIENCE (2018)

Article Medicine, Research & Experimental

Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease

Rudy Chang et al.

MOLECULAR PHARMACEUTICS (2018)

Review Physiology

From Erythroblasts to Mature Red Blood Cells: Organelle Clearance in Mammals

Martina Moras et al.

FRONTIERS IN PHYSIOLOGY (2017)

Review Clinical Neurology

Neuroinflammation in Alzheimer's disease

Michael T. Heneka et al.

LANCET NEUROLOGY (2015)

Article Biochemistry & Molecular Biology

Widespread Expression of Erythropoietin Receptor in Brain and Its Induction by Injury

Christoph Ott et al.

MOLECULAR MEDICINE (2015)

Review Hematology

Physiology and Pharmacology of Erythropoietin

Wolfgang Jelkmann

TRANSFUSION MEDICINE AND HEMOTHERAPY (2013)

Review Clinical Neurology

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

Peter T. Nelson et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)

Review Clinical Neurology

Erythropoietin: still on the neuroprotection road

Nelvys Subiros et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2012)

Article Behavioral Sciences

Early behavioural markers of disease in P301S tau transgenic mice

Maria Luisa Scattoni et al.

BEHAVIOURAL BRAIN RESEARCH (2010)

Article Clinical Neurology

Tau in Alzheimer Disease and Related Tauopathies

K. Iqbal et al.

CURRENT ALZHEIMER RESEARCH (2010)

Review Pharmacology & Pharmacy

Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!

Paul A. Lapchak

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)

Article Pharmacology & Pharmacy

Drug Targeting of Erythropoietin Across the Primate Blood-Brain Barrier with an IgG Molecular Trojan Horse

Ruben J. Boado et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)

Article Medicine, Research & Experimental

Re-Engineering Erythropoietin as an IgG Fusion Protein That Penetrates the Blood-Brain Barrier in the Mouse

Qing-Hui Zhou et al.

MOLECULAR PHARMACEUTICS (2010)

Review Biochemistry & Molecular Biology

Iron trafficking inside the brain

Torben Moos et al.

JOURNAL OF NEUROCHEMISTRY (2007)

Article Endocrinology & Metabolism

Blood-brain barrier genomics

JY Li et al.

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2001)